MODEL VERDICT
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
Insufficient data to determine relative valuation for DMAA.
Fair value could not be computed for DMAA due to insufficient comparable data.
DMAA's current P/E of -186.6x compares to the industry median of 33.3x (5 peers in the group). This represents a -660.1% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
No analyst coverage data is available for DMAA.
The model confidence score is 38/100, based on: data completeness (0), peer quality (25), historical depth (5), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows weak agreement across inputs — interpret with caution.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for DMAA.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.